Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies

Overview of attention for article published in Drug Safety, June 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#19 of 1,888)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 24 news outlets

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 4 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 24 news stories from 24 outlets.

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Morning Star, 18 Jun 2024

—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC…

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Stockwatch, 18 Jun 2024

—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC…

News story from Finanz Nachrichten on Tuesday 18 June 2024

Finanz Nachrichten, 18 Jun 2024

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Crwe World, 18 Jun 2024

—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 20 additional news stories.